amneal report non-gaap dilut ep revenu compar
street estim respect remain wed target
double-digit long-term lt ebitda growth still strike us overli sanguin given
amrx major gener peer think respect core gener
busi quit way though depth amrx gener pipelin
lost us believ exposur higher-valu product uncertain lt market
dynam non-substitut opana er gener gener levothyroxin along
realiti limit competit higher-valu gener launch harder come
point murki visibl double-digit lt growth point attract
risk/reward profil ebitda reiter neutral rate
lower pt see detail
fairli wide ebitda guidanc rang lower end look realist
view amrx ebitda guidanc rang impli growth rate
though reflect competit headwind associ hand key gener
 vagifem voltaren gel aggrenox well loss albenza exclus also
reflect meaning contribut new gener launch launch given
albenza gener cite margin significantli higher
corpor margin believ fair wonder even meaning top-lin
contribut new launch margin new gener suffici
make eros higher-margin asset therefor suffici drive
ebitda comfort bottom end rang one could argu
start contribut levothyroxin render guidanc realist
would keep mind product share econom potenti
addit competit not-too-dist futur
word busi develop surmis manag look
aggress given revenu gener
given footprint brand busi unlik grow given eventu loss
zomig nasal spray exclus may though rytari continu bright
spot volum growth year-to-d respect per
iqvia believ would behoov take aggress approach
addit brand/specialti asset mean diversif
higher-margin diversif also mean better leverag
neurology-focus commerci infrastructur compani call nearli movement
disord specialist beyond movement disord easili absorb
product focus therapeut adjac within broader neurolog space plu
particularli effici sale forc essenti support one product
price competit risk gener product
amneal focus primarili gener market
price close februari
ep disc
debt total capit
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
actual versu pjc consensu estim
consensu estim
compani report factset pjc estim
compani report factset pjc estim
page
million except per shareactualspjc estimatesstreet gener administr except per guidanceestimatesexpens itemsadjust gross tax share
consensu
compani report factset pjc estim
page
million except per brand sale brand gener administr tax share exhibit
note gross sale base iqvia symphoni health solut sale data disclos specif product sale data figur may exact
brand discount gross net sale respect revenu build
acquir part amneal acquisit gemini reflect pjc estim
compani report pjc estim
revis pt
new pt base price-to-earnings unchang
ep estim versu prior ep estim discount
unchang one year unchang new pt translat
ebitda multipl premium amrx major gener
peer group someth nod manag comment continu
expect long-term double-digit ebitda growth though admittedli doubt
regard compani abil deliv aspir target
page
sale brand gross brand net net pharma sale salestot gross gener gener amneal quarterli annual incom statement
million except ep
zomig brand sale
sale
sell gener administr
patent litig
incom loss tax
item net tax
expens revenu
sell gener administr
sell gener administr
ipxl began provid individu brand product sale earlier reflect pjc estim corepharma includ albenza emverm model reflect impact albenza gener competit start late
exclud cost relat remedi effort hayward ca manufactur facil
follow complet merger ameanl provid pro forma financi valu may reflect pjc estim
financi prior reflect legaci ipxl begin sale reflect amneal legaci ipxl sale
acquir part amneal acquisit gemini reflect pjc estim report net sale product
proprietari piper jaffray co februari
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
